Gilead purchased 15 million newly issued shares of common stock at a price of $1.4167 per shareFollowing the close of the transaction on December 20, 2023, Gilead holds 19.4% of HOOKIPA’s outstanding shares of common stockEquity investment is to advance the Gilead-partnered HIV therapeutic program through Phase 1; trial expected to commence in the first half of 2024 NEW YORK and VIENNA, Austria, Dec.

吉利德以每股1.4167美元的价格购买了1500万股新发行的普通股。2023年12月20日交易结束后，吉利德持有HOOKIPA普通股流通股的19.4%，股权投资将推动吉利德合作的艾滋病毒治疗计划通过第一阶段；审判预计于2024年上半年在纽约和奥地利维也纳开始。

21, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that Gilead Sciences (‘Gilead’) has purchased 15 million shares of HOOKIPA’s common stock for approximately $21.25 million, at a price of $1.4167 per share.

2023年21月21日（环球新闻网）--HOOKIPA Pharma Inc.（纳斯达克：HOOK，“HOOKIPA”）是一家基于其专有的沙粒病毒平台开发新型免疫治疗药物的公司，今天宣布吉利德科学公司（Gilead Sciences（“Gilead”）以约2125万美元的价格购买了1500万股HOOKIPA的普通股，每股价格为1.4167美元。

In addition, HOOKIPA has the right, subject to certain terms and conditions, to sell an additional approximately $8.75 million of common stock to Gilead as pro-rata participation in potential future equity raises. The agreement with Gilead replaces the stock purchase agreement that Hookipa entered into with Gilead in 2022.

此外，HOOKIPA有权根据某些条款和条件，向吉利德额外出售约875万美元的普通股，作为按比例参与未来可能的股权融资。与吉利德的协议取代了Hookipa于2022年与吉利德签订的股票购买协议。

“We have a tremendous partnership with Gilead, who have been incredible believers in our arenavirus platform since our initial collaboration and license agreement began more than five years ago,” said Joern Aldag, Chief Executive Officer at HOOKIPA. “Together, we have made meaningful progress to find a potential functional cure for HIV.

HOOKIPA首席执行官乔恩·奥尔达格（JoernAldag）表示：“我们与吉利德（Gilead）建立了巨大的合作伙伴关系，自从五年多前我们达成最初的合作和许可协议以来，吉利德一直是我们沙粒病毒平台的难以置信的信徒。”。“我们共同努力，在寻找治疗艾滋病毒的潜在功能方面取得了有意义的进展。

Most recently, we received clearance from the U.S. Food and Drug Administration of our Investigational New Drug application for HB-500 and are excited to begin our Phase 1 trial in the first half of next year. We are excited to continue our relationship with Gilead, and we are collectively optimistic about the potential of our partnership to benefit patients.” The transaction c.

最近，我们收到了美国食品和药物管理局批准的HB-500研究性新药申请，并很高兴在明年上半年开始我们的第一阶段试验。我们很高兴能继续与吉利德的关系，我们对我们的合作关系在造福患者方面的潜力感到乐观。”交易c。